Radiofrequency ablation of Bethesda category III thyroid nodules with benign molecular testing: Preliminary findings from a single institution.

IF 2.7 3区医学 Q1 SURGERY

American journal of surgery Pub Date : 2024-08-23 DOI:10.1016/j.amjsurg.2024.115929

Young Jae Ryu, Shawn Y Hsu, Eric J Kuo, Rachel Liou, Catherine M McManus, James A Lee, Jennifer H Kuo

{"title":"Radiofrequency ablation of Bethesda category III thyroid nodules with benign molecular testing: Preliminary findings from a single institution.","authors":"Young Jae Ryu, Shawn Y Hsu, Eric J Kuo, Rachel Liou, Catherine M McManus, James A Lee, Jennifer H Kuo","doi":"10.1016/j.amjsurg.2024.115929","DOIUrl":null,"url":null,"abstract":"Background: The efficacy of radiofrequency ablation (RFA) in treating thyroid nodules with indeterminate cytology remains less studied. The objective of this study was to determine the efficacy of RFA in treating nodules with Bethesda III that have been molecularly profiled benign (BIII-MPN).Methods: We included prospectively enrolled patients who underwent RFA for benign and BIII-MPN thyroid nodules. Primary outcome measures were volume reduction ratio (VRR), symptom score (range 0-10), and cosmetic score (range 0-3) at 1, 3, 6, and 12 months after RFA, as well as complication rates.Results: A total of 258 nodules in 192 patients were included (benign: 238 in 174; BIII-MPN: 20 in 18). The median VRR differed insignificantly, whereas symptom and cosmetic score improvements were similar between two cohorts. BIII-MPN thyroid nodules were associated with lower rates of infection and temporary voice change.Conclusion: Our preliminary findings suggest that RFA may be a feasible management option for BIII-MPN thyroid nodules. However, appropriate will be important to address the important risk of potentially missed malignancies.","PeriodicalId":7771,"journal":{"name":"American journal of surgery","volume":null,"pages":null},"PeriodicalIF":2.7000,"publicationDate":"2024-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.amjsurg.2024.115929","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The efficacy of radiofrequency ablation (RFA) in treating thyroid nodules with indeterminate cytology remains less studied. The objective of this study was to determine the efficacy of RFA in treating nodules with Bethesda III that have been molecularly profiled benign (BIII-MPN).

Methods: We included prospectively enrolled patients who underwent RFA for benign and BIII-MPN thyroid nodules. Primary outcome measures were volume reduction ratio (VRR), symptom score (range 0-10), and cosmetic score (range 0-3) at 1, 3, 6, and 12 months after RFA, as well as complication rates.

Results: A total of 258 nodules in 192 patients were included (benign: 238 in 174; BIII-MPN: 20 in 18). The median VRR differed insignificantly, whereas symptom and cosmetic score improvements were similar between two cohorts. BIII-MPN thyroid nodules were associated with lower rates of infection and temporary voice change.

Conclusion: Our preliminary findings suggest that RFA may be a feasible management option for BIII-MPN thyroid nodules. However, appropriate will be important to address the important risk of potentially missed malignancies.

查看原文本刊更多论文

通过良性分子检测对 Bethesda III 类甲状腺结节进行射频消融：一家医疗机构的初步发现

背景：关于射频消融（RFA）治疗细胞学不确定的甲状腺结节的疗效的研究仍然较少。本研究的目的是确定射频消融治疗贝塞斯达 III 型结节（BIII-MPN）的疗效：我们纳入了接受RFA治疗良性和BIII-MPN甲状腺结节的前瞻性入组患者。主要结果指标为RFA术后1、3、6和12个月的体积缩小率（VRR）、症状评分（范围0-10）和外观评分（范围0-3）以及并发症发生率：结果：共纳入了 192 名患者的 258 个结节（良性：174 人中有 238 个；BIII-MPN：18 人中有 20 个）。两组患者的VRR中位数差异不大，而症状和外观评分改善情况相似。BIII-MPN甲状腺结节的感染率和暂时性变声率较低：我们的初步研究结果表明，RFA可能是治疗BIII-MPN甲状腺结节的可行方案。结论：我们的初步研究结果表明，RFA可能是治疗BIII-MPN甲状腺结节的可行方案，但必须适当处理可能漏诊的恶性肿瘤这一重要风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American journal of surgery 医学-外科

CiteScore

5.00

自引率

6.70%

发文量

570

审稿时长

56 days

期刊介绍： The American Journal of Surgery® is a peer-reviewed journal designed for the general surgeon who performs abdominal, cancer, vascular, head and neck, breast, colorectal, and other forms of surgery. AJS is the official journal of 7 major surgical societies* and publishes their official papers as well as independently submitted clinical studies, editorials, reviews, brief reports, correspondence and book reviews.